Table 3.

Prevalence of Nonmedical Use (NMU) for Xtampza ER and Comparators by Route of Administration (7/1/2016–12/31/2019)

	Past 30-Day Xtampza ER NMU		Past 30-Day Other Oxycodone ER NMU		Past 30-Day Oxycodone IR NMU
	n	%	n	%	n	%
Total NMU Mentions*	73	100.0	4114	100.0	31,281	100.0
Route of Administration**
Any Oral**	45	61.6	3261	79.3	21,977	70.3
Swallow whole	38	52.1	2262	55.0	15,498	49.5
Chew then swallow	5	6.8	658	16.0	4287	13.7
Dissolve like a cough drop	2	2.7	230	5.6	1489	4.8
Dissolved in liquid then drank	0	0.0	111	2.7	703	2.2
Any non-oral**	21	28.8	2380	57.9	18,787	60.1
Chi-square, Any Non-Oral (p-value)	Index Group		18.57 (<0.001)		52.47 (<0.001)
Snort	13	17.8	1314	31.9	12,696	40.6
Smoke	3	4.1	165	4.0	1250	4.0
Inject	5	6.8	901	21.9	4841	15.5
Other	8	11.0	189	4.6	685	2.2

Notes: *Total NMU mentions are the total number of products within each drug group/category that respondents endorsed for past 30-day NMU. Assessments may have endorsed multiple drugs in any category and product/comparator categories are not mutually exclusive. **Multiple drugs and multiple routes of administration for each drug could be selected by respondents for each product/comparator. Any mention of any route of administration for each product/opioid group is included. Thus, the total number of routes may be greater than total NMU mentions. Italic font indicates statistically significant finding. Results in bold represent the collective categories of oral and non-oral routes of administration while results in regular font represent subsets within each group (subsets are not mutually exclusive).

Abbreviations: ER, extended-release; IR, immediate-release; NMU, nonmedical use.